Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Biontech Cell & Gene Therapies Gmbh

Biontech Se

Tron-translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz

Astellas Pharma Gmbh

Biontech Rna Pharmaceuticals Gmbh

Petra Oehm

Ugur Sahin

Ozlem Tureci

Özlem Türeci

Tana Omokoko

Christian Bender

Ralf-Holger Voss

Martin Löwer

Claudia Paret

Kirsten Vormbrock

Karolina Anna Mroz

Kathleen Hobohm

Andrea Breitkreuz

Barbara Schrörs

Katharina Reinhard

Thomas Bukur

Lisa Hebich

Ralf Holger Voss

Janina Caspar

Matthias Birtel

Martin Suchan

Benjamin Rengstl

Kristina Michel

This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.

Methods for characterizing loss of antigen presentation

The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

Claudin-18.2-specific immunoreceptors and T cell epitopes

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

Antigen receptors and uses thereof

Growing community of inventors

Mainz, Germany

Petra Oehm